Fumitremorgins and Relatives – From Tremorgenic Compounds to Valuable Anti-Cancer Drugs

Title:Fumitremorgins and Relatives – From Tremorgenic Compounds to Valuable Anti-Cancer Drugs

Volume: 25 Issue: 2

Author(s): Wolf-Rainer Abraham*

Affiliation:

• Helmholtz Centre for Infection Research, Chemical Microbiology, Braunschweig,Germany

Keywords: Diketopiperazines, cyclic dipeptides, fumitremorgin, cyclotryprostatin, norgeamide, anti-cancer, drug resistance, ABCG2 transporter

Abstract: Background: Fumitremorgins are mycotoxins but can also inhibit cancer cells and reverse their drug resistance.

Objective: The bioactivity of prenylated cyclo-Trp-Pro dipeptides and their derivatives concerning their application in anti-cancer therapies will be discussed.

Methods: Reports on the discovery and assessment of this class of fungal compounds are compiled from literature using Google Scholar and PubMed. The bioactivities of the natural compounds are discussed with the aim of their improvement for cancer therapy.

Results: Although a number of compounds of this class have been found, only a minority of them showed bioactivity in the applied bioassays. Fumitremorgins and related compounds are active against various cancer cells but they are also mycotoxins. Some of these natural compounds can arrest cancer cells in their cell cycle and some can block ABC-transporters and reverse resistance in chemotherapy. Structure activity relationships have been deduced leading to the prediction of highly active compounds. Several easily accessible derivatives of these natural products have been discovered being highly selective and non-toxic.

Conclusion: Sophisticated screening methods, high throughput screening, metabolic engineering, and synthetic biology are novel and promising technologies for the search for highly active drugs. Rapid gene sequencing in combination with engineered biosynthetic pathways should contribute substantially to novel pharmaceutics.

Cite this article as:

Abraham Wolf-Rainer *, Fumitremorgins and Relatives – From Tremorgenic Compounds to Valuable Anti-Cancer Drugs, Current Medicinal Chemistry 2018; 25 (2) . https://dx.doi.org/10.2174/0929867324666170724103410